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HEAD & NECK CANCER 
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Head and Neck Cancer (HNC) 
Malignant Tumors 
Squamous cell carcinoma (SCC) 
•  Most common primary cancer 
(> 90%) 
•  Differentiation 
 (well-moderate-poor)  
 based on keratinization 
Other carcinomas 
•  Adenocarcinoma 
•  Mucoepidermoid carcinoma 
•  Lymphoepithelioma 
Lymphomas 
•  Non-Hodgkin’s 
•  Hodgkin 
Sarcomas 
Metastatic cancers 
•  Lung 
•  GI tract 
•  Breast 
 
From Haddad RI, Shin DM. N Engl J Med 2008; 359: 1143-54 
  Head and Neck Cancer 
Models of Genetic Instability and Progression in Head and Neck Cancer 
•  5-6% of all cancers (about 650.000 new cases/year) 
•  > 90% squamous cell origin (Western world) 
•  Risk factors:  
–  tobacco smoking   - poor oral health 
–  alcohol use    - mechanical irritation 
–  betel chewing   - occupational exposure 
–  HPV     - malnutrition 
•  Localized disease 40%, regional mets 50% distant mets 10% 
•  2/3 locally/regionally advanced 
•  Major threat: local recurrence, SPT, SFT 
Head and Neck Cancer 
Epidemiology and clinical presentation 
Head and Neck Cancer 
Typical symptoms by site 
Site of origin    Early Symptoms 
Nasopharynx   Hearing loss, tinnitus, epistaxis 
  nasal obstruction, single lymph node (LN) 
 
Oral cavity    Superficial mucosal pain, denture  
   malposition, mouth bleeding 
 
Glottic larynx    Hoarseness (glottic) 
 
Supraglottis/oropharynx          Dysphagia or otalgia (supraglottic) 
Hypopharynx   
 
   
 
O 
O’Sullivan et al, 1999 
 
Work-up in SCCHN 
•  Physical examination 
•  Endoscopical evaluation (EUA)* 
•  Biopsy of the primary lesion 
•  FNA in case of a suspected lymph node 
•  Imaging techniques (CT, MRI, PET) 
•  Careful dental evaluation recommended 
NB. Open biopsies of neck masses are reserved if all clinical 
       and radiological studies cannot reveal the primary tumor  
EUA= examination under anesthesia 
TNM Staging 
N0 N1 N2 N3 
T1 I  
 
 
 
III 
 
 
 
 
IVa3, b4, c5 
T2 II 
T3 
T4a1 
T4b2 
1 resectable; 2 unresectable; 3 advanced resectable; 4 advanced unresectable; 
 5 distant metastatic  
Diagnosis and Staging Procedures 
Conclusions 
•  Being aware of risk factors (e.g. tobacco, alcohol, HPV) and 
early signs a/o symptoms of crucial importance for early 
diagnosis 
•  Clinical and endoscopical evaluations play the most 
important role in the diagnostic work-up of SCCHN 
•  Imaging techniques very useful in refining the extent of the 
disease 
•  Accurate staging very important for decision making 
•  Open biopsies of neck masses only when all clinical and 
radiological studies cannot reveal the primary tumor. 
•    
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Considerations in Decision Making 
•  Disease factors (e.g. site, stage, biology [HPV, 
EGFR], specific risk factors for locoregional or 
distant relapse) 
•  Patient factors (e.g. age, sex, performance status, 
lifestyle habits, socio-economic status) 
•  Treatment factors (radiotherapy, chemotherapy, 
targeted therapy, surgery)1 
•  What do patients want? 
1Schantz SP et al. Cancer: Principles & Practice of Oncology, 6th ed. 2001; 797-860 
What do Patients Look For? Prioritizing Treatment Outcomes 
List MA er al. Head Neck 2004;26:163-170 
“Survival seems to be of paramount 
importance to both patient and non patient 
groups, overshadowing associated toxicities 
and potential dysfunction” 
Treatment Modalities in SCCHN 
2014 
•  Surgery    as single modality* 
•  Radiotherapy  (RT)   or in combination 
•  Chemotherapy (CT)** 
–  combined modality treatment (CMT):  
   Induction CT (ICT); concomitant CT and RT (CCRT); 
sequential therapy (ICT → CCRT); adjuvant CT (ACT); 
postoperative CCRT 
–  Palliative therapy 
•  Targeted therapy (TT)** 
–  Alone or combined with RT, CMT or palliative CT 
* In early disease; ** in locoregionally advanced and recurrent/metastatic disease 
EHNS-ESMO-ESTRO  Clinical Practice 
Guidelines 2010 
Locoregionally advanced disease 
Level of 
evidence 
Grade of 
recommendation 
Surgery → RT or CCRT I A 
Concomitant CT and RT* I A 
Cetuximab plus RT II B 
ICT → RT  and CCRT for 
organ preservation 
II A 
 
ICT → CCRT  
  
investigational 
 
*in case of mutilating surgery and in nonresectable disease 
Gregoire V et al, Ann Oncol 2010: 21 (suppl 5): VI84-VI86 
Acute adverse effects: Grade ≥3 
p<0.05 
ns 
Patients (%) 
p<0.01 
Wendt TG, et al. J Clin Oncol 1998;16:1318–1324 
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Xerostomia 
Nausea/emesis 
Leukopenia 
Dermatitis 
Mucositis 
RT alone (n=140) 
CCRT (n=130) 
ns, not significant 
CCRT = CDDP + 5-FU + RT 
 Late Toxicity  
 Analysis of 230 patients receiving CCRT in 3 studies  
 (RTOG 91-11, 97-03, 99-14) 
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 Machtay M, et al. J Clin Oncol 2008; 26: 3582–3589 
Methods to Reduce the Toxicity of 
Cisplatin-based CCRT in SCHN 
Better ballistics  
•  CT – MRI – (PET) 
•  IGRT 
New radiotherapy techniques 
•  IMRT and SW-IMRT 
•  Stereotactic radiotherapy 
•  IMPT 
RT sensitization with cytotoxics other than CDDP 
RT sensitization with biological agents  
CT= computed tomography; MRI= magnetic resonance imaging; IGRT= image-guided RT; IMPT intensity-modulated 
particle therapy; IMRT= intensity-modulated RT; PET= positron emission tomography; RT= radiotherapy 
Enhancement of Radiation 
Effects 
Selective 
Targeting of 
Hypoxic 
Cells 
Induction of 
Pro-Apoptotic 
Mechanisms 
Anti- 
Angiogenesis 
Strategies 
Inhibition of 
Cox-2 
Replacement 
of Mutated 
Tumor Suppressor 
Genes 
Inhibition of  
EGFR 
Several biological mechanisms that have potential to alter sensitization strategies (Choy and MacRae, 2003) 
Cetuximab: Properties and Mechanism 
of Action 
•  IgG1 monoclonal antibody 
•  Specifically binds to the EGFR with 
higher affinity than its natural ligands 
(TGFα, EGF), thus competitively 
inhibiting their binding 
•  High affinity: Kd = 0.39 nM 
•  Induces apoptosis and ADCC1 
•  Preclinical synergistic activity 
in combination with 
chemotherapy and 
radiotherapy 
ADCC = antibody-dependent cellular cytotoxicity  
Cetuximab + RT in locally advanced SCCHN: 
Study design 
Bonner et al. N Engl J Med 2006; 354: 567-578 
RT as before + 
ERBITUX initial 400 mg/m2 2-h  
infusion then 250 mg/m2 1-h infusion  
weekly for at least 7 doses  
RT 
once or twice daily or  
concomitant boost for 7 – 8 weeks 
 
Patients with measurable locally advanced SCCHN  
(stratified by KPS;node+/0;T1-3/4; RT regimen) 
Randomization 
Follow-up until disease progression or up to 5 years 
Cetuximab in Locally Advanced SCCHN 
Cetuximab + RT 
significantly increases 
median duration of 
locoregional control vs RT 
alone by 10 months 
Cetuximab + RT  
5-year survival update 
LRC (months) 
LRC in OPC Subpopulation According to p16 Status and 
Treatment Effect of RT + Cetuximab vs RT Alone 
RT; p16 – 
No. at risk OPC p16 evaluable (n=182) 
RT p16 negative 64 31 17 3 0 0 
RT p16 positive 34 24 20 12 6 0 
RT + cet p16 negative 43 21 16 6 2 0 
RT + cet p16 positive 41 33 30 21 12 0 
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RT + cet; p16 + 
RT; p16 + 
RT + cet; p16 – 
  
LRC interaction test p=NS 
HR=0.31 [0.11–0.88] 
32% 
20% 
87% 
65% 
HR=0.78 [0.49–1.25] 
Rosenthal et al. ASCO 2014 (Abstract #6001) 
Chemoradiation and Bioradiation 
50 trials, 9615 pts (MA)* 1 trial, 424 patients 
HR of death 0.74 (0.67-0.82)+ HR of death 0.74 (0.57-0.97)** 
Main effect on local failure 
Modest effect on DM 
Only effect on local failure 
No effect on DM 
Efficacy irrespective of site and of 
fractionation schedule 
Effect may be site and RT schedule 
specific 
Significant acute toxicity which may 
inflict on late toxicity, in particular 
swallowing dysfunction 
Grade 3-4 mucositis and radiation 
dermatitis not significantly increased. 
Late toxicity does not seem 
increased. High compliance. 
No direct comparison in phase III reported 
* Pignon et al, Radioth Oncol 2009: 92; 4-14 (level I evidence); **Bonner et al. N Engl J Med 2006; 354: 567-578 (level II evidence); 
+with mono Platin therapy 
RTOG 0522: Study Objective & Design 
Test hypothesis that adding cetuximab to the radiation-
cisplatin platform for frontline therapy of stage III-IV 
HNSCC improves progression-free survival (PFS) 
Stage III & IV* SCC of: 
 • Oropharynx 
 •  Larynx 
 •  Hypopharynx 
Stratify : 
 • Lx vs Non-Lx 
 •  N0 vs N1-2b vs N2c-3 
 • Zubrod PS  
 •  3-D vs IMRT 
 •  PET (yes vs no)   
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1.  AFX-CB: 72 Gy/42 F/6 W +  
 Cisplatin: 100 mg/m2, q3W x 2 
2.  AFX-CB: 72 Gy/42 F/6 W +  
 Cisplatin: 100 mg/m2, q3w x 2 
 Cetuximab: 400 mg/m2 x1,  then 
250 mg/m2/w 
 
Excluded T1N+, T2N1 
Ang KK et al, ASCO 2011 (abstract #5500) 
RTOG 0522 
Progression-Free Survival & Overall Survival 
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P= 0.66 (log-rank, 1-sided) 
2-Year Rate (95% CI) 
64.3% (59.7, 68.8) Cisplatin 
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Years after Randomization 
0 1 2 3 
# Patients at Risk 
448 385 266 96 
447 378 251 94 
Hazard Ratio (95% CI) 
0.87 (0.66, 1.15) 
P= 0.17 (log-rank, 1-sided) 
2-Year Rate (95% CI) 
79.7% (75.9, 83.6) Cisplatin 
82.6% (78.9, 86.3) Cisplatin+Cet 
Primary Endpoint 
Ang KK et al, ASCO 2011 (abstract #5500) 
Randomized Trials of Sequential Therapy 
versus Concurrent Chemoradiation Only 
Group  Regimen   Survival benefit 
 
                                     TPF (or PF) x 3 → CCRT (P)   No 
TTCC (Sp)1 
                                     CCRT (cisplatin) 
 
                                     TPF x 3 → CCRT (C or TAX)   No 
Boston (US)2 
                                     CCRT (cisplatin) 
 
                                      TPF x 2 → CCRT (THFX)   No 
Chicago (US)3 
                                      CCRT (THFX) 
   
                                      CCRT (PF) w/wo foregoing  TPF  Yes   
GCTCC (It)4   
                                      BRT (Cetuximab) w/wo foregoing TPF 
1Hitt et al, Ann Oncol 2013, Nov 19 Epub [ahead of print]; 2Haddad et al, Lancet Oncol 2013; 14: 257-296 
3Cohen et al, ASCO 2012 (abstr. #5501); 4Ghi et al, ASCO 2013  (abstr. #6003) and ASCO 2014 (abstr. #6004) 
Locoregionally Advanced SCCHN 
Conclusions 
 
Stages III/IV(M0) patient categories: resectable, unresectable 
and those treated for organ preservation 
Treatment strategies: 
 
1.  Surgery → adjuvant RT or concurrent CRT (CCRT) 
2.  Definitive CCRT , with surgery as an optional salvage or 
completion treatment 
 
3.  Definitive RT + cetuximab (bioradiation; BRT), with surgery 
as an optional salvage or completion therapy 
4.  Induction CT → definitive local therapy (RT, CCRT, BRT) 
 
 
CRT= chemoradiation with cisplatin; BRT= bioradiation 
Failure Rate after Primary Therapy 
for SCCHN 
SCCHN is largely a locoregional problem, with distribution of 
most recurrences after primary, curative-intent RT regimens 
occuring within the treatment field1. 
 
MACH-NC analysis (50 trials of CCRT vs RT alone) at 5 years: 
•  Local and/or regional recurrences:   
    - CCRT arm: 50.8%  
 - Control (RT alone) arm: 60.1%  
•  Distant recurrences below 20%2 
1Strojan et al. Head & Neck-DOI 10.1002/hed.23542 
2Pignon et al. Radiother Oncol 2009; 92: 4-14 
Factors to be Considered when Choosing  
Treatment Options in R/M-Disease 
•  Type of relapse and time interval “primary TRT-Relapse” 
•  Type of treatment received in the curative setting 
•  Performance status 
•  Comorbidities 
•  Patient preference  
•  Logistics 
Recurrent/Metastatic SCCHN 
Treatment Options 
•  Surgery  
–  The treatment of choice for non-metastatic second primary 
or recurrent SCCHN in patients with sufficient good health  
–  Best chance for cure: patients with early-stage recurrent 
tumors and recurrent cancer of the larynx 
•  Re-irradiation (± radiosensitizing agents) 
–  Following salvage surgery 
–  For unresectable disease 
•  Systemic treatment 
•  Best supportive care only 
Randomized Trial of Postoperative CRT after 
Salvage Surgery versus Salvage Surgery alone in 
SCCHN 
Observations with CRT: 
•  ↓ Locoregional failure (21 vs 34 patients) 
•  ↑ Tumor-related death (5 vs 0 patients) 
•  ↑ Distant metastasis (6 vs 3 patients) 
•  ↑ Second primary tumor (4 vs 1 patients) 
•  ↑ Late severe toxicity (40% vs 10%) 
Janot F, et al. J Clin Oncol 2008;26:5518–5523 
Salvage Surgery and Adjuvant Re-irradiation1 
Series No. of  
pts 
RT dose  
(Gy) 
CT % late 
≥ G3 tox 
Outcome at 2 years 
Emami 1987 48 NS no NS OS 46% 
Bechalal 1997 14 60 no 50% LC 27%, OS 36% 
De Crevoisier 2001 25 60 HU+5FU NS OS 48% 
Machtay 2004 16 60 P+5FU 38% LRC 100%, OS 81% 
Kasperts 2006 39 60-66% No NS LRC 74%, OS 67% 
Salama 2006 49 60-74 HU+5FU NS LRC 68%, OS 39%2 
Suh 2008 12 50.5 Yes, 42% 33% OS 52% 
Janssen 2010 20 46 yes, 35% NS LRC 21%, OS 24% 
 
1Conventional techniques; 23-years data (modified from Strojan et al, 2013) 
Re-irradiation in Unresectable SCCHN 
(conventional techniques) 
*3 year data 
1RTOG Multicenter study, many cases without CT-based planning (CF–RT ± chemotherapy): median survival 10–11 months 
2University of Chicago experience: RT dose, surgery, cisplatin, paclitaxel, and gemcitabine were prognostic  
GTV, gross tumor volume; LN, lymph node; RT, radiotherapy (modified from Strojan et al, 2013) 
Series N 
Targets + 
margins  
(cm) 
Median re-
irradiation 
dose (Gy) 
± Chemo-
therapy 
Late grade 
 ≥3 toxicity 
(%) 
2-year OS  
(%) 
De Crevoisier, 19981 169 GTV + (1.5–2) 65 (+) 50 21 
Schaefer, 2000 32 GTV + 2 40–50 + 15 10 
Hehr, 2005 27 GTV + 1  40 + N/A 18* 
Kramer, 2005 38 GTV + 2 50–60 + 38 35 
Salama, 20062 114 GTV + 1 + LN 64 + 18 22* 
Langer, 2007 99 GTV + 2 + LN 65 + 38 25 
Spencer, 2008 79 GTV + 2 60 + 23 15 
Independent Prognostic Factors 
•  Interval since last radiation 
•  Organ dysfunction1 
•  Charlson comorbidity index2 (per index increase) 
•  ACE-27  comorbidity grade3 (per grade increase) 
•  Recurrent T-stage (T0-T4) 
•  Tumor bulk after salvage surgery (per cm increase) 
•  Reirradiation dose (≤ 50 Gy or > 50 Gy) 
1feeding tube dependency, functioning tracheostomy, soft tissue defect including uncovered open wound of 
skin or mucosa, fistula, osteonecrosis 
2weighted index of 19 clinical conditions; 3severity of comorbidity based on 26 disease systems 
Tanvetyanon et al. J Clin Oncol 2009; 27: 1983-1991 
 
 
Locoregional Recurrences: Conclusions 
Algorithm for reirradiation 
Strojan et al. Head & Neck- DOI 10.1002/hed.23542 
Recurrent/Metastatic SCCHN 
Medical Treatment 
 
•  Supportive care only 
•  Single agent chemotherapy 
•  Multiagent chemotherapy 
•  Targeted therapy (single agent or combined) 
•  Targeted agents combined with cytotoxics 
•  Immunotherapy 
•  Other approaches (BNCT, HT, ECT, PDT) 
BNCT= boron neutron capture therapy; HT= hyperthermia; ECT= electrochemotherapy; PDT= photodynamic therapy 
Single Agents with Activity+ in R/M-SCCHN* 
 Conventional drug  % RR        Newer agents            %RR   
Cyclofosfamide    36             Edetrexate    6-21 
Methotrexate    31             Pemetrexed          26 
Vinblastine    29             Vinorelbine                6-22 
Cisplatin    28             Irinotecan                     21 
Ifosfamide    26             Capecitabine   8-22 
Carboplatin    25             S-1           27 
Doxorubicin    24             Orzel           21 
Bleomycin    21             Paclitaxel            20-43 
5-Fluorouracil    15             Docetaxel            20-42 
 • Pooled data in advanced disease (from Vermorken JB; In Bernier J (ed.) Head and Neck Cancer: Multimodality Management, 
Springer Science+Business Media, LLC 2011; +Activity defined as ≥15% responses 
 
Randomized Single Agent Trials in R/M-SCCHN 
Author  No. of  Drugs  RR   OAS (mo) 
(year)     pts  randomized  %   median 
 
Schornagel    264                    MTX                    16                 6.0 
(1995)                             EDX                     21                 6.0 
 
Grose   100  MTX  16   4.6 
(1985)    DDP  8   4.1 
 
Hong   38  MTX  23   6.1 
(1983)    DDP  29   6.3 
 
Vermorken   95  MTX  16   6.8 
(1999)    PACL  11  (-23)  6.5 
 
Guardiola   57  MTX  15   3.9 
(2004)    DOCE  27   3.7 
 MTX= methotrexate; EDX=edetrexate, DDP= cisplatin; PACL=paclitaxel; DOCE= docetaxel 
Platinum Combinations vs Single Agents  
Randomized trials in R/M disease 
Investigator N Regimen ORR (%) 
Median OS 
(months) 
Significant 
OS benefit 
Jacobs et al 
1992 
249 
Cisplatin + 5-FU 
Cisplatin 
5-FU 
 32* 
17 
13 
5.5 
5.0 
6.1 
No 
Forastiere et al 
1992 277 
Cisplatin + 5-FU 
Carboplatin + 5-FU 
Methotrexate 
  32* 
 21 
10 
6.6 
5.0 
5.6 
No 
Clavel et al 
1994 382 
CABO 
Cisplatin + 5-FU 
Cisplatin 
  34*  
  31* 
15 
7.3 
7.3 
7.3 
No 
Urba et al 
2012 795 
Cisplatin/Pemetrexed 
Cisplatin/placebo 
12 
8 
7.3 
6.3 
No 
*Statistically significant  
Jacobs et al, J Clin Oncol 1992; Forastiere et al. J Clin Oncol 1992; Clavel et al. Ann Oncol 1994 ; Urba et al, Cancer 2012 
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Gibson MK, et al. J Clin Oncol 2005;23:3562–3567 
Plateau in survival at ~24 months 
E1395: No significant difference in 
survival between PF and TP 
Study arm 
1-year 
survival, % 
[95% CI] 
Median 
OS, 
months OR, % 
Grade 3/4 
toxicity 
Cisplatin + 5-FU (n=104) 
Cisplatin + paclitaxel 
(n=100) 
41.4 [23–42] 
32.4 [23–42] 
8.7 
8.1 
30% 
26% 
Reduced for 
cisplatin + 
paclitaxel 
E1395: Efficacy and Safety 
PF 
(n=104) 
TP 
(n=100) 
CR + PR, % 29.8 26 
CR, % 6.7 7 
Median survival, months 8.7 8.1 
1-year survival, % 41 32 
Grade 3–5 toxicity, % 
   ANC 67 55 
   PLT 23 4 
   Hb 33 13 
   Infection 21 13 
   Diarrhea 6 1 
   Stomatitis 31 0 
Gibson MK, et al. J Clin Oncol 2005;23:3562–3567 
Unfavorable Predictors of Outcome in HNC 
R/M disease 
Based on data from E 1393 and E 1395 (n=399) 
Median FUP: 4.75 years 
Median OS: 7.8 months  1 yr  2 yr  3 yr  5 yr 
Survival   32%  12%  7%  3.6% 
Predictors for RR:  weight loss, PS, RD, site other than OP, 
 history of RT, WD/MD tumors 
Factors for OS:  weight loss, PS, PD (favorable), OC/HP 
 history of RT 
Factors for TTP:  PD (favorable), OC/HP, history of RT 
 < 2 adverse PF → Median survival  1 year 
 3-5 adverse PF → Median survival  0.5 year 
 
Argiris et al, 2004  
Treatment of Platinum-Refractory R/M-SCCHN 
Retrospective data 
•  Best supportive care (BSC) 
Chemotherapy (CT) 
Radiation therapy (RT) 
Other local therapies 
•  In a retrospective analysis of 151 patients with platinum-
refractory disease 45% received BSC, and 55% any form of 
treatment (Leon et al, Clin Oncol 2005; 17: 418-424) 
•  Overall response rate was 2.6%, the clinical benefit rate 
15.2%, and survival 103 days. 
(for patients receiving BSC 56.5 days, CT 107 days) 
Second-Line Treatment in R/M-SCCHN 
Phase II/III data 
Reference Drug Prior CT for R/
M-SCCHN 
Median PFS 
(months) 
Median OS 
(months) 
Pivot1 MTX 62%       1.5      3.7 
Stewart2 MTX unclear       NA      6.7 
Machiels3 BSC+MTX78% 45%(55%<6mo)       1.9      5.2 
Numico4 docetaxel 61%       4.0 (TTP)      6.0 
Zenda5 docetaxel unclear       1.7      4.6 
Specenier6 docetaxel 77%       1.7      4.1 
Argiris7 docetaxel unclear       2.1(TTP)      6.0 
1 Ann Oncol 2001; 2 J Clin Oncol 2009; 3 Lancet Oncol 2011; 4 Ann Oncol 2002 
5 Jpn J Clin Oncol 2007; 6 Am J Clin Oncol  2011; 7 J Clin Oncol 2013 
Cytotoxic Chemotherapy in R/M-SCCHN 
Conclusions 
•  Single agent methotrexate is still a standard of care 
•  Platinum-based combinations are superior in terms of response 
rate (but at the cost of more toxicity), no survival benefit 
•  In first-line setting, median survival is 6-9 months and 1-year 
survival rates vary between 20% and 40% 
•  Once platinum-resistance occur, outlook is very poor 
•  R/M SCCHN patients are candidates for phase I and phase II trials 
of experimental therapeutics 
Targets for Next-generation Therapy 
Tumor cell 
3 
3. Signal transduction pathways 
 Ras, raf, MAPK, MEK, ERK, AKT
 protein kinase C, PI3K 
Nucleus 
1 
1. Growth factors and  
 growth-factor receptors 
 HER family, c-kit/SCFR 
2 
2. Extracellular matrix/ 
 angiogenic pathways 
 VEGFR, integrins, MMPs 
4 
4. Cell-survival pathways  
 Cyclin-dependent kinases, 
 mTOR, cGMP, COX-2, p53, Bcl-2 
5. Protein production 
Proteasome 
5 
EGFR-targeting Agents under Clinical 
Investigation in SCCHN 
Monoclonal antibodies    Toxicity 
Cetuximab  IMC225  chimeric human/murine  IgG1  skin 
Matuzumab  EMD72000  humanized mouse  IgG1  skin 
Nimotuzumab  h-R3  humanized mouse  IgG1  systemic/hemodynamic 
Zalutumumab  2F8  human  IgG1  skin 
Panitumumab  ABX-EGF  human  IgG2  skin 
Tyrosine kinase inhibitors 
Gefitinib  ZD1839  reversible  EGFR  skin/gastrointestinal (GI) 
Erlotinib  OSI-774  reversible  EGFR  skin/GI 
Lapatinib  GW-572016 reversible  EGFR/erbB2  skin/GI/systemic 
Afatinib  BIBW-2992  irreversible  Pan Her*  skin/GI/systemic 
Dacomitinib        PF-00299804  irreversible  Pan Her*  skin/oral/GI/systemic 
 
 * EGFR/Her2/Her4 
Cetuximab in Platinum Pretreated Patients 
with R/M-SCCHN 
 
Author 
 
Phase 
 
N 
 
Regimen 
ORR 
(%) 
Median PFS 
(months) 
Median OS 
(months) 
Vermorken 
2007  II 103 cetuximab  13 2.3 (TTP) 5.9 
Baselga 
2005 II 96 cetuximab + Platinum  10 2.8 (TTP) 6.1 
Herbst 
2005 II 79 cetuximab + Cisplatin  10 2.2 (TTP) 5.2 
Knoedler  
2013 II 84 cetuximab + Docetaxel  11 3.1 6.7 
Baselga et al. JCO 2005; Herbst et al. JCO 2005;   
Knoedler et al. Oncology 2013; Vermorken et al. JCO 2007 
Anti-EGFR TKIs in R/M-SCCHN 
Drug	   Phase/ prior CT	   Reference	   Resp. Rate,%	  
Erlotinib  	   II    0-1 lines	   Soulieres, JCO, 2004  4	  
Gefitinib	   II    0-1 lines	   Cohen, JCO, 2003	    11	  
II    0-5 lines	   Cohen, CCR, 2005	    2	  
II    0-1 lines	   Kirby, BJC, 2006	    9	  
III   Pt+ / Pt- 
       
Stewart, JCO, 2009 
	  
 3-8	  
Lapatinib	   II    unclear	   Abidoye, ASCO 2006	    0	  
Afatinib  II R   prior Pt 	   Seiwert,  Ann Oncol 2014	       16/8* 
            	  
Dacomitinib II	  	  	  	  no	  prior	  Pt	   Siu,	  JCO	  2011	   	  	  	  	  	  	  	  	  	  	  	  	  	  13	  
Prior CT= for recurrent/metastatic disease (* by IR/ICR) 
Second-line Treatment with Anti-EGFR Drugs 
Randomized trials in R/M-SCCHN 
Study/Reference N Regimen RR (%) PFS OS (mo) 
IMEX 
Stewart et al,  
J Clin Oncol 2009 
 
486 Gefitinib (250 mg) 
Gefitinib (500 mg) 
Methotrexate 
 2.7 
 7.6 
 3.9 
ND 
ND 
ND 
5.6 
6.0 
6.7 
ECOG 1302 
Argiris et al,  
J Clin Oncol 2013 
 
270 D + Gefitinib 
D + placebo 
12 
 
6 
3.5 (TTP) 
2.1 (TTP) 
7.3 
6.0 
ZALUTE  
Machiels et al,  
Lancet Oncol 2010 
286 Z + BSC (-MTX) 
BSC (optional MTX) 
 6 
 1 
2.3* 
1.9* 
6.7° 
5.2° 
BSC = best supportive care; Z = zalutumumab; MTX = methotrexate; ND = no data; TTP= time to progression 
*HR (95% CI): 0.62 (0.47-0.83), p=0,0010; °HR (95% CI): 0.77 (0.57-1.05), p=0.0648 
Stewart et al, J Clin Oncol 2009; 11: 1864-1871 
Phase III Study of Gefitinib vs Methotrexate 
Second-line treatment in R/M SCCHN 
First-line Treatment with Anti-EGFR MoAbs 
Randomized trials in R/M-SCCHN 
Study/Reference N Regimen RR (%) PFS (mo) OS (mo) 
ECOG 5397/ 
Burtness et al   
J Clin Oncol 2005 
117 Cisplatin + cetuximab 
Cisplatin + placebo 
 26a 
 10 
 4.2 
 2.7 
 9.2 
 8.0 
EXTREME/ 
Vermorken et al  
N Engl J Med 2008 
442 PF1 + cetuximab 
PF1 
 36a 
 20 
 5.6b 
 3.3 
 10.1c 
 7.4 
SPECTRUM/ 
Vermorken et al  
Lancet Oncol 2013 
657 PF2 + panitumumab 
PF2 
 36a 
 25 
 5.8b 
 4.6 
 11.1 
 9.0 
PF1 = cisplatin or carboplatin plus 5-FU; PF2 = cisplatin plus 5-FU 
a, b, c: significant differences 
EXTREME: Phase III Study Design 
cetuximab 
until PD 
R/M SCCHN 
•  Prior CT 
•  KPS (<80 vs ≥80) CT + cetuximab 
 Primary endpoint: OS 
 Secondary endpoints: PFS, RR, safety 
CT  
Cisplatin (100 mg/m2 IV, day 1) or 
Carboplatin (AUC 5, day 1) +  
5-FU (1000 mg/m2 IV, days 1–4) 
Every 3 weeks, up to 6 cycles 
cetuximab 
Initial dose 400 mg/m2 
then 250 mg/m2 weekly 
until progressive disease (PD) 
N=442 
CT  
Vermorken et al. NEJM 2008 
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EXTREME: Overall Survival 
HR=0.80 [95% CI: 0.64–0.99] 
p=0.04 
CT (n=220) 
CT + cetuximab (n=222) 
 
Vermorken et al. NEJM 2008 
7.4 
months 
EXTREME: Relationship between  
EGFR Expression and Survival 
HR [95% CI] 
Benefit favors CT + cetuximab Benefit favors CT alone 
EGFR %  
positive cells 
Median OS: CT + cetuximab vs CT 
1 2 5 10 20 30 0.5 0.2 0.1 
0% (n=8; 2%) 
>0–40% (n=64; 14%) 
≥40% (n=341; 77%) 
Missing (n=29; 7%) 
HR [95% CI] 
1.98 [0.32–12.25] 
0.72 [0.40–1.28] 
0.75 [0.59–0.95] 
1.24 [0.51–3.02] 
3.1 vs 13.7 
10.9 vs 7.8 
10.1 vs 7.1 
4.6 vs 11.3 
Modified from Vermorken et al. NEJM 2008 
EXTREME: Retrospective Analysis of EGFR 
Gene Copy Number 
OS PFS RR 
CT CT + cetuximab CT 
CT + 
cetuximab CT 
CT + 
cetuximab 
FISH+ 7.2 mo 10.5 mo 3.1 mo 6.2 mo 11.8% 36.0% 
FISH- 7.8 mo 10.6 mo 4.1 mo 5.7 mo 22.3% 34.3% 
FISH+ vs FISH- HR 1.04 HR 1.02 HR 1.05 HR 0.86 OR 0.46  OR 1.08 
95% CI [0.71–1.51] [0.69–1.51] [0.71–1.54] [0.58–1.27] [0.18–1.22]  [0.54–2.18] 
cetuximab + CT patients: 50 FISH+, 108 FISH-; CT patients: 51 FISH+, 103 FISH- 
HR: Hazard ratio 
OR: Odds ratio 
 
Licitra et al. Ann Oncol 2010 
 
 
Overall Survival in EXTREME by p16 Status 
p16+ patients 
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Months 
Number of patients at risk Number of patients at risk 
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0.4 
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0.7 
0.8 
0.9 
1.0 
0 3 6 9 12 15 18 21 24 27 
CT + cetuximab (n=18) 
CT (n=23) 
CT + cetuximab (n=178) 
CT (n=162) 
 18  15  12  11  10   8   6   4   1   0 
 23  18  17  12   7   6   3   2   1   0 
178 150 126  93  61  40  19  10   1   0 
162 128  92  56  47  33  15   6   0   0 
HR (95% CI)  0.63 (0.30–1.34) 
p-value 0.22 
HR (95% CI)  0.82 (0.65–1.04) 
p-value 0.11 
HRs are CT + cetuximab vs CT; CI, confidence interval; HR, hazard ratio 
. 
 Vermorken et al, Ann Oncol 2014 
EXTREME: Symptom Control 
QLQ-H&N35 module 
Modified from Mesía et al. Ann Oncol 2010 
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p=0.0027 p=0.0162 p=0.5702 p=0.0787 p=0.0694 p=0.7732 p=0.2237 
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EXTREME: Safety Profile 
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CT + cetuximab 
(n=219) 
Vermorken et al. NEJM 2008 
EXTREME – Overall Survival 
Long-term follow-up 
Vermorken et al. ASCO 2014 (abstr. #6021) 
Cetuximab and Beyond 
Conclusions 
•  Cetuximab has palliative value comparable to methotrexate and 
taxanes in second therapy and can be used as a control arm to test 
other targeted agents. 
 
•  PF + cetuximab is a new standard regimen in 1st-line SCCHN for 
good-risk patients with benefit regardless of known biomarkers 
•  However, long-term survival with this regimen still disappointing 
•  Therefore, studies combining cetuximab with other cytotoxic agents, 
with other anti-EGFR compounds, with dual compounds or pan-HER 
inhibitors, and other noval targeted agents or combinations are 
ongoing 
 
•  Confirmatory studies on the prognostic/predictive value of p16/HPV 
in R/M-SSCHN are needed.  
CT plus Cetuximab in First-Line SCCHN 
Taxane regimens promising 
 
Author 
 
Phase 
 
N 
 
Regimen 
ORR 
(%) 
Median PFS 
(months) 
Median OS 
(months) 
Vermorken 
2008 III 442 
PF  
PF + cetuximab 
 20 
 36* 
 3.3 
 5.6* 
 7.4 
 10.1* 
Burtness  
2005 III 117 
Cis + Placebo 
Cis + cetuximab 
 10 
 26* 
 2.7 
 4.2 
 8.0 
 9.2 
Buentzel 
2007 II 23 
Pacli/Carbo + 
cetuximab  56  5.0**        8.0 
Hitt  
2011 
II 46 Pacli + cetuximab  54  4.2    8.1 
Guigay 
2012 II 54 Doce/Cis /cetuximab 54  7.1 15.3 
*Significant; **TTP 
Vermorken et al. NEJM 2008; Burtness et al. JCO 2005;  
Hitt et al. Ann Oncol 2011; Buentzel et al. ASCO 2007; Guigay et al. ASCO 2012 
Treatment schedule 
Guigay et al (ASCO 2012; abstract 5505) 
Docetaxel 
Cisplatin 
Cetuximab 
Until progression or 
unacceptable toxicity 
Every 2 weeks 
Maintenance: 
cetuximab alone 
Day 1 Day 8 Day 15 Day 22 Day 29 
Evaluation after 2 cycles:  
if ORR or SD [ 2 additional cycles  
1e 1 cycle 
Chemotherapy + cetuximab:Up to 4 cycles 
Docetaxel i.v. (75 mg/m² every 3 weeks) 
Cisplatin i.v. (75 mg/m² every 3 weeks) 
Cetuximab i.v. (400 mg/m² at day 1 then 250 mg/m² 
once a week) 
Cetuximab i.v. (500 mg/m² every 2 
weeks) 
G-CSF (lenograstim) delivered after every cycle 
Docetaxel / Cisplatin plus Cetuximab (TPE) 
Safety* 
  
Toxicity     Grade 3 (%)  Grade 4 (%) 
 
Skin rash      15    - 
HSR            6    - 
Febrile neutropenia      6    - 
Non-febrile neutropenia     6          11 
Diarrhea        3.7    - 
      
*Grade 3-4 toxicities occurring>5% 
Guigay et al (ASCO 2012; abstract 5505) 
 
 
TPExtreme TRIAL - GORTEC 2014-01 
PI: J Guigay 
 
 
•  Cetuximab weekly until 
progression or unacceptable 
toxicity 
Control arm  (EXTREME) 
(6 cycles every 3 weeks ) 
Cisplatin: 100 mg/m2 iv 
5FU: 4000 mg/m2 during 96h in continuous 
infusion 
Cetuximab: 400 mg/m2 iv  (loading dose), then 250 
mg/m2 iv   
 
•  Cetuximab every 2 weeks until 
progression or unacceptable 
toxicity 
Experimental arm (TPEx) 
(4 cycles every 3 weeks )  
Cisplatine: 75 mg/m2 iv 
Docetaxel: 75 mg/m2 iv 
Cetuximab: 400 mg/m2 iv (loading dose), 
then 250 mg/m2 iv 
 
+ G CSF after each cycle 
6
6 
SCCHN  
R/M 1st line 
(N = 416) 
 
!  Age < 71 y 
!  PS < 2 
!  Previous: 
cddp < 300mg/m2 
anti-EGFR > 1y 
R 
Phase II  
(R 1:1) 
Minimization on :  
PS 
Metastatic status, 
Previous cetuximab 
Country 
!  Primary objective: OS 
!  Ancillary studies: QOL, cost-effectiveness, p16 / HPV tumor status 
Completed Randomized Trials in First-Line 
Recurrent/Metastatic SCCHN 
Study/Reference N Regimen RR (%) PFS (mo) OS (mo) 
ECOG 5397/ 
Burtness et al   
J Clin Oncol 2005 
117 Cisplatin + cetuximab 
Cisplatin + placebo 
 26a 
 10 
 4.2 
 2.7 
 9.2 
 8.0 
EXTREME/ 
Vermorken et al  
N Engl J Med 2008 
442 PF1 + cetuximab 
PF1 
 36a 
 20 
 5.6b 
 3.3 
 10.1c 
 7.4 
SPECTRUM/ 
Vermorken et al  
Lancet Oncol 2013 
657 PF2 + panitumumab 
PF2 
 36a 
 25 
 5.8b 
 4.6 
 11.1 
 9.0 
PF1 = cisplatin or carboplatin plus 5-FU; PF2 = cisplatin plus 5-FU 
a, b, c: significant differences 
SPECTRUM: Overall Survival by p16 Status 
Median OS  
(95% CI) months 
Pmab + CT (n = 165) 11.8 (9.8 - 14.0) 
CT alone (n = 153) 8.6 (6.9 - 11.3) 
P16- patients P16+ patients 
Median OS  
(95% CI) months 
 Pmab + CT (n = 56)  10.9 (7.1 - 12.6) 
CT alone (n = 37) 12.1 (7.6 - 17.4) 
Quantitative interaction test p-value = 0.332 
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HR = 0.96 (95%CI: 0.59 - 1.57) 
p-value = 0.88 
HR = 0.73 (95%CI: 0.57 - 0.94) 
p-value = 0.02 
 
Relationship p16/HPV Status and Outcomes 
in R/M-SCCHN 
Drugs Type of  
Study 
Study  
Group 
Disease  
Site 
Prognostic / 
predictive 
 
-  PF ± Cetuximab1 Phase III EXTREME All* Yes/no 
-  PF ± Panitumumab2 Phase III SPECTRUM All* Yes/Yes 
-  PF vs PT3 Phase III ECOG 1395 All* Yes/ NR 
-  CPT-11 + docetaxel3 Phase II ECOG 3301 All* Yes/NR 
* Hypopharynx, oral cavity, larynx and oropharynx (OPC) 
1Vermorken et al, Ann  Oncol 2014;  2Vermorken et al, Lancet Oncol 2013; 3Mehra et al, ASCO 2013, abstract 6006 
 
•  EGFR is a validated therapeutic target in SCCHN 
•  Discordance between EGFR expression and response 
Possible mechanisms of resistance 
•  EGFR mutations 
•  Increased EGFR internalization 
•  Parallel signaling pathways, such as 
–  IGF-1R, MET, erbB2 
–  PI3K/AKT mutations 
–  Cycline D1 amplification 
The Problem of Resistance 
Examples of Strategies to Overcome 
Resistance to  Anti-EGFR Drugs 
•  Blockage of multiple HER receptors 
 - Lapatinib: oral reversible dual TKI of EGFR and HER2 
 - Afatinib and dacomitinib: irreversible pan-HER inhibitors 
 
•  Dual targeting mAbs or mixture of mAbs 
 - MEHD7945A (DAF):  –Randomized phase II vs cetuximab in patients    
    progressing on/after Pt-CT (NCT01577173) 
 - Catumaxomab (anti-EpCAMxanti-CD3), cytotoxicity assay1 
 - Ertumaxomab (anti-HER2/neuxanti-CD3), cytotoxicity assay1 
 - Sym004 (mixture of 2 mAbs targeting non-overlapping epitopes on EGFR) 
  
Other Novel Targeted Agents in SCCHN 
•  Anti-angiogenesis 
–  VEGF 
–  VEGFR 
•  Integrin inhibitors 
•  Histone deacetylase inhibitors                  No phase III  
•  PI3K/Akt/mTOR pathway inhibitors           Data available 
•  Proteasome inhibitors 
•  IGFR inhibitors 
•  SRC inhibitors 
                      
Basis for Immune therapy – Immune Escape 
 
•  Expression of PD-L1 
on  
    a) tumor cells &      
    b) macrophages  
    can suppress immune 
    surveillance.  
 
•  In mouse models 
antibodies blocking 
PD-1 / PD-L1 
interaction  lead to 
tumor rejection 
•  Clinical prognosis 
correlates with 
presence of TILs and 
PD-L1 expression in 
multiple cancers. 
Presented by: Tanguy Seiwert Melero I et al. Clin Cancer Res 2013;19:997-1008 
A Phase Ib Study of Pembrolizumab (MK-3475) in 
Patients with HPV-negative and HPV-positive 
Head & Neck Cancer 
Presented at ASCO 2014  by: 
Tanguy Seiwert, MD 
Assistant Professor of Medicine 
Associate Director Head and Neck Cancer Program 
Fellow, Institute for Genomics and Systems Biology 
The University of Chicago 
Tanguy Seiwert, Barbara Burtness, Jared Weiss, Iris Gluck, J. Paul Eder, Sara I. 
Pai, Marisa Dolled-Filhart, Kenneth Emancipator, Kumudu Pathiraja, Christine 
Gause, Robert Iannone, Holly Brown, Jennifer Houp, Jonathan Cheng, Laura Q. 
Chow  
Efficacy: Waterfall Plot* 
Presented by: Tanguy Seiwert (ASCO 2014; abstr. 6011) 
51% (26/51) of patients had decreased tumor burden   
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"  Best percent change from baseline in target lesions (site assessment) delineated by HPV status 
 
*as of May 23, 2014; Includes only patients with RECIST measurable lesions at baseline and at least 1 follow-up scan 
(n=51) 
Best Overall Response*  
Presented by: Tanguy Seiwert (ASCO 2014; abstr. 6011) 
     56 pts evaluable for  
     Response 
Total Head/neck  
N=56† 
HPV (+) 
N=20 
HPV (-) 
N=36§ 
Response Evaluation	   n (%) 	   95% CI† 	   n (%) 	   95% CI† 	   n (%) 	   95% CI† 	  
  Complete Response	   1 (1.8)      (0.0, 9.6)      1 (5.0)      	   (0.1, 24.9)     	   0 (0.0) (0.0, 9.7) 
  Partial Response	   10 (17.9)      (8.9, 30.4)     3 (15.0)	   (3.2, 37.9)    	   7 (19.4) (8.2, 36.0) 
  Best Overall Response 
    (Complete + Partial)‡	    11 (19.6)        (10.2, 32.4)      4 (20.0)     	    (5.7, 43.7)     	   7 (19.4) (8.2, 36.0) 
  Stable Disease	   16 (28.6)       (17.3, 42.2)    8 (40.0)    	   (19.1, 63.9)   	   8 (22.2) (10.1, 39.2) 
  Progressive Disease	   25 (44.6)      (31.3, 58.5)    7 (35.0)  	   (15.4, 59.2)   	   18 (50.0) (32.9, 67.1) 
  No Assessment	   4 (7.1)        (2.0, 17.3)     1 (5.0)       	   (0.1, 24.9)    	   3 (8.3) (1.8, 22.5) 
Based on RECIST 1.1 Per site assessment; includes confirmed and unconfirmed responses 
†61 patients eligible for treatment; 60 patients dosed; 56 patients eligible for pre-defined full analysis set.   
‡A single patient with PD followed by PR on treatment was classified as PR. 
§Includes 2 patients for whom HPV data unavailable. 
† Based on binomial exact confidence interval method. 
•  PD-L1 expression correlates with Response 
•  Using a Youden-Index derived, preliminary PD-L1 cut point: 
#  Above cutpoint: 45.5% (5/11) RR 
#  Below cutpoint: 11.4% (5/44) RR 
*as of May 23, 2014 
Presented by: 
Presented by Dr. Seiwert , ASCO 2014 
Take-Home Messages 
•  Better understanding of the biology of SCCHN has led to change in 
treatment approaches 
•  Concurrent CRT is standard of care for locoregionally advanced SCCHN 
•  Bioradiation (cetuximab) an alternative option for patients with contra-
indications for or intolerance of concurrent CRT 
•  Addition of cetuximab to platinum/5-fluorouracil in patients with R/M-SCCHN 
→ benefit in median survival; long-term survival remains disappointing  
•  A plethora of new targeted therapies are in various stages of preclinical and 
clinical development 
•  Reactivation of immune surveillance by blocking PD1 interaction with its 
ligands possibly a promising approach for HNC 
